超滤(肾)
腹膜透析
连续不卧床腹膜透析
医学
二十碳糊精
透析
色谱法
泌尿科
化学
外科
作者
Olof Heimbürger,Jörgen Hegbrant,Giedre Martus,Martin Wilkie,Charlotte De Leon,Ola Carlsson,Alf Johansson
出处
期刊:Clinical Journal of The American Society of Nephrology
[American Society of Nephrology]
日期:2023-10-30
卷期号:19 (2): 224-232
被引量:3
标识
DOI:10.2215/cjn.0000000000000342
摘要
Background Volume overload is common in patients treated with peritoneal dialysis (PD) and is associated with poor clinical outcome. Steady concentration PD is where a continuous glucose infusion maintains the intraperitoneal glucose concentration and as a result provides continuous ultrafiltration throughout the dwell. The primary objective of this study was to investigate the ultrafiltration rate and glucose ultrafiltration efficiency for steady concentration PD in comparison with a standard continuous ambulatory PD (CAPD) dwell, using the novel Carry Life UF device. Methods Eight stable patients treated with PD (six fast and two fast average transporters) were investigated four times: a standard 4-hour CAPD dwell with 2 L of 2.5% dextrose solution as control and three 5-hour steady concentration PD treatments (glucose dose 11, 14, 20 g/h, initial fill 1.5 L of 1.5% dextrose solution). All investigations were preceded by an overnight 2 L 7.5% icodextrin dwell. Results Intraperitoneal glucose concentration increased during the first 1–2 hours of the steady concentration PD treatments and remained stable thereafter. Ultrafiltration rates were significantly higher with steady concentration PD treatments (124±49, 146±63, and 168±78 mL/h with 11, 14, and 20 g/h, respectively, versus 40±60 mL/h with the control dwell). Sodium removal and glucose ultrafiltration efficiency (ultrafiltration volume/gram glucose uptake) were significantly higher with steady concentration PD treatments versus the control dwell, where the 11 g/h glucose dose was most efficient. Conclusions Steady concentration PD performed with the Carry Life UF device resulted in higher ultrafiltration rates, more efficient use of glucose (increased ultrafiltration volume/gram glucose absorbed), and greater sodium removal compared with a standard 2.5% dextrose CAPD dwell. Clinical Trial registry name and registration number A Performance Analysis of the Peritoneal Ultrafiltration (PUF) Achieved With the Carry Life ® UF, NCT03724682.
科研通智能强力驱动
Strongly Powered by AbleSci AI